Stevens-Johnson syndrome (SJS) is a severe mucocutaneous adverse drug reaction with a relatively high mortality rate. SJS is described during herpes simplex virus type 1 (HSV1) infection and, rarely, even during adalimumab therapy. We report the case of a patient with Crohn's disease who developed SJS during an HSV1 infection and a contemporaneous anti-TNF alpha therapy with adalimumab. Remission was achieved with suspension of adalimumab and high doses of intravenous steroids and antivirals. Patients with HSV1 infection and on adalimumab therapy have a combined risk of SJS and should be monitored closely.
Stevens-Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn's Disease / Roselli, Jenny; Innocenti, Tommaso; Lynch, Erica Nicola; Parisio, Laura; Apolito, Pasquale; Mello, Tommaso; Macrì, Giuseppe; Milla, Monica; Biagini, Maria Rosa; Tarocchi, Mirko; Milani, Stefano; Galli, Andrea. - In: CASE REPORTS IN GASTROINTESTINAL MEDICINE. - ISSN 2090-6528. - ELETTRONICO. - 2020:(2020), pp. 1-3. [10.1155/2020/3875024]
Stevens-Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn's Disease
Roselli, Jenny;Innocenti, Tommaso;Lynch, Erica Nicola;Parisio, Laura;Apolito, Pasquale;Mello, Tommaso;Macrì, Giuseppe;Milla, Monica;Biagini, Maria Rosa;Tarocchi, Mirko;Milani, Stefano;Galli, Andrea
2020
Abstract
Stevens-Johnson syndrome (SJS) is a severe mucocutaneous adverse drug reaction with a relatively high mortality rate. SJS is described during herpes simplex virus type 1 (HSV1) infection and, rarely, even during adalimumab therapy. We report the case of a patient with Crohn's disease who developed SJS during an HSV1 infection and a contemporaneous anti-TNF alpha therapy with adalimumab. Remission was achieved with suspension of adalimumab and high doses of intravenous steroids and antivirals. Patients with HSV1 infection and on adalimumab therapy have a combined risk of SJS and should be monitored closely.File | Dimensione | Formato | |
---|---|---|---|
CRIGM2020-3875024.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
1.09 MB
Formato
Adobe PDF
|
1.09 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.